Who are AZM X mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clindamycin Topical Gel 1%, AzaSite Eye Drops, Tedizolid IV, Azithromycin and amoxicillin, Azithromycin 3 days, azithromycin (AZ).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azm-x-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AZM X mg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZM X mg (AZM X mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious diseases.

phase 3 Macrolide antibiotic 50S ribosomal subunit Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

AZM X mg (AZM X mg) — Celltrion. Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZM X mg TARGET	AZM X mg	Celltrion	phase 3	Macrolide antibiotic	50S ribosomal subunit
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
AzaSite Eye Drops	AzaSite Eye Drops	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Tedizolid IV	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
azithromycin (AZ)	azithromycin (AZ)	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

Pfizer · 6 drugs in this class
Grünenthal GmbH · 4 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
University of Taubate · 2 drugs in this class
Lihir Medical Centre · 2 drugs in this class
Thomas Jefferson University · 2 drugs in this class
Copenhagen Studies on Asthma in Childhood · 1 drug in this class
Ain Shams Maternity Hospital · 1 drug in this class
Celltrion · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZM X mg — Competitive Intelligence Brief. https://druglandscape.com/ci/azm-x-mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing